Romani L, Puccetti P, Grohmann U, Cenci E, Mage M G, Fioretti M C
Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy.
Int J Immunopharmacol. 1989;11(5):537-42. doi: 10.1016/0192-0561(89)90183-5.
To determine whether a novel pattern of lymphokine production might be involved in the superior immunogenicity of chemically xenogenized tumors over that of parental cells, we tested a panel of murine tumors xenogenized by DTIC for production of soluble factors with lymphokine-like activity and induction of lymphokine release from naïve or specifically sensitized lymphocytes. In the L5178Y tumor system, a majority of xenogenized but not parental clones produced an IL-1-like factor, and this was associated, as a rule, with class II antigen expression and antigen-presenting ability. However, no such properties were exhibited by the xenogenized variants of P815 and L1210Ha cells, which nevertheless occasionally expressed other lymphokine (GM-CSF, IL-3) activities. On examining the ability of xenogenized and parental tumors to cause release of IL-1, IL-2, IL-3, IFN-gamma, TNF/LT and GM-CSF from T-cells, we found, as a rule, an increased lymphokine production when lymphocytes primed in vivo to a xenogenized tumor were restimulated in vitro with the same or parental cells.
为了确定一种新的淋巴因子产生模式是否可能参与化学异种源肿瘤比亲代细胞具有更高免疫原性的过程，我们检测了一组用达卡巴嗪进行异种源化的小鼠肿瘤，以检测其产生具有淋巴因子样活性的可溶性因子的能力，以及诱导未致敏或特异性致敏淋巴细胞释放淋巴因子的能力。在L5178Y肿瘤系统中，大多数异种源化而非亲代克隆产生一种IL-1样因子，通常这与II类抗原表达和抗原呈递能力相关。然而，P815和L1210Ha细胞的异种源化变体未表现出此类特性，不过它们偶尔会表达其他淋巴因子（GM-CSF、IL-3）活性。在检测异种源化肿瘤和亲代肿瘤引起T细胞释放IL-1、IL-2、IL-3、IFN-γ、TNF/LT和GM-CSF的能力时，我们发现，通常情况下，当体内用异种源化肿瘤致敏的淋巴细胞在体外被相同或亲代细胞再次刺激时，淋巴因子的产生会增加。
